TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Treadmill exercise test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise adherence rates
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cost-utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of life as rated by family members
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: median time to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: grade 2 toxicity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: grade 3 toxicity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: TFF rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of overly light anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bispectral index values above the recommended upper limit of 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of GAD65A in bipolar disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of ATPA in bipolar disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heart Rate (HR) 30 and 60 minutes postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fever (≥38.0°C)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Upper Respiratory Tract Symptoms (URTS)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Upper Respiratory Tract Symptoms (URTS)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of >=1-grade improvement from baseline for lentigines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of >=1-grade improvement from baseline for mottled hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of >=50% global improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tac predose concentration above target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hemoptysis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical response criteria achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of osteonecrosis of the jaw (ONJ)
Endpoint domain: Adverse events/effects
Primary endpoint: Delayed healing of lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of hip, vertebral and nonvertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete surgical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU-acquired bloodstream infection with MDRGNB
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalizations for diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalizations for fever
Endpoint domain: Adverse events/effects
Primary endpoint: RUTTS score <30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-density lipoprotein cholesterol elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Remnant lipoprotein cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low apolipoprotein B/A-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of SNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelium-dependent vasodilatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of prokinetic agents compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum ICAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum P selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of endoscopy procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical non-evidence of disease (bNED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum late genitourinary toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum late gastrointestinal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of acute graft-versus-host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time to eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time to toe movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lucidity and cooperation in recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of vomiting within the first 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital discharge times
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: general self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete cytoreduction CC0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: No major morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: No relapse
Endpoint domain: Mortality/survival
Primary endpoint: Overall knowledge of cardiovascular risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total number of Primary Care visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Transfusion of packed red blood cells and fresh frozen plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of cTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Values of aPTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: average state anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of suicide attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Uterine size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of death or heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of death, heart failure, or final LVEF <45%
Endpoint domain: Mortality/survival
Primary endpoint: lumen volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in correct responses on follow-up survey
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mortality and myocardial infarction (MI) prediction during initial 72-hour period
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac risk prediction (mortality, MI) at six-month follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Repeated coronary revascularization prediction at six-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of rigidity at the base of the penis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of rigidity at the tip of the penis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of erections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of antimicrobial prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day in-hospital mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in serodiscordant receptive anal intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in meth-using days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean survival time of PED/PEA‐15-positive expression group
Endpoint domain: Mortality/survival
Primary endpoint: Negative rates of serum IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T(es) temperature measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 9HPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ARAT pinch section
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular Rate (VR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: efficiency of the EZ device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: safety of the EZ device
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in SDQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rt increases to bronchoconstriction suggestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of stay in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to first CID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to sustained CID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C5a production across the filter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Production of elastase and MPO across the filter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentrations of MPO at the inlet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of infants with Mental Developmental Index <85
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: No recurrence of BCC
Endpoint domain: Mortality/survival
Primary endpoint: bother from hot flashes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grip and pinch measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in articular cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in daily NSAID use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of severe blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in inflammation measured by BASDAI, BASFI, CRP, and ASDAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in MRI inflammation measurements (SPARCC scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of FDL in the lumbar spine
Endpoint domain: Adverse events/effects
Primary endpoint: CRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement of serum lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visceral fat/total fat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delivery timing between 23.00 hours and 08.00 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Relative risk for delivery by vacuum or forceps
Endpoint domain: Adverse events/effects
Primary endpoint: Deep vein thrombosis or pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sensitivity of InflammaDry in diagnosing dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of InflammaDry in diagnosing dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depression symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to PV disconnection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF recurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Primary ischemic strokes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cerebrovascular outcomes
Primary endpoint: Intracranial bleeding risks
Endpoint domain: Adverse events/effects
Primary endpoint: Second stroke rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cerebrovascular outcomes
Primary endpoint: Typical histological features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atypical histological features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No relapse after excision
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma levels of MR‐proADM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Z-scores of height-for-age, weight-for-age, and weight-for-height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in heart failure symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic transaminases increase
Endpoint domain: Adverse events/effects
Primary endpoint: Patients' awareness and understanding of clinical trial issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patients' satisfaction with the intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risperidone exposure accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risperidone/9-OH-RIS ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nursing home placement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: DXA rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoporosis detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New osteoporosis prescription rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of DSM diagnostic criteria for cannabis use disorder (CUD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ERAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MTCT probability at age 15 months
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of HIV pretest counselling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of women taking more than 80% of zidovudine regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time free of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of POCD 7 days postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vaizey incontinence score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insertion times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of major coronary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient satisfaction cosmetic score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area of sway in quiet standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sway in moving state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total sway in quiet standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear film thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial-dependent vasodilation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in DAS28 erythrocyte sedimentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in DAS28 C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients positive for antidrug antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: requirement for the use of rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevention of alcohol misuse and alcohol-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentine loss following tooth brushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean clarithromycin concentrations in gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival crevicular fluid flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLR loss per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Satisfaction with Project MOVE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Project MOVE
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in total FIQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean C(max) and AUC(0-∞) of amuvatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile (no serious or severe adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time with SpO(2) <90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Obstructive apnoeas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Non-cortical micro-awakenings per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: percent of patients losing fewer than 15 letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of patients with preserved or improved BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decrease in foveal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean frequency of oral ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing time of oral ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain of oral ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle total creatine increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-legged performance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak torque increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDI Subjective Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with MADRS score≥15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In‐stent late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Clinician‐Administered PTSD Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard ratio of HIV seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly time in moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of i.v. locks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of infiltration
Endpoint domain: Adverse events/effects
Primary endpoint: stool symptom score on PAC-SYM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: abdominal discomfort score on CSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preference for CPR and intubation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status